Mehta Rupal, Ying Gui Shuang, Houston Samuel, Isakova Tamara, Nessel Lisa, Ojo Akinlolu, Go Alan, Lash Jim, Kusek John, Grunwald Juan, Wolf Myles
Division of Nephrology and Hypertension, Department of Medicine and Center for Translational Metabolism and Health, Institute for Public Health and Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
University of Pennsylvania, Philadelphia, PA, USA.
Nephrol Dial Transplant. 2015 Sep;30(9):1534-41. doi: 10.1093/ndt/gfv123. Epub 2015 Apr 24.
Elevated circulating concentrations of phosphate and fibroblast growth factor 23 (FGF23) contribute to the pathogenesis of cardiovascular disease in chronic kidney disease (CKD). Retinopathy is a common manifestation of microvascular disease in CKD, but its associations with phosphate and FGF23 have not been studied. We tested the hypothesis that higher serum phosphate is associated with more severe retinopathy in individuals with CKD, independent of FGF23 and known risk factors for retinopathy.
We tested the associations of serum phosphate and plasma FGF23 with retinopathy in a cross-sectional analysis of 1800 participants in the Chronic Renal Insufficiency Cohort Study who underwent fundus photography. Retinopathy severity was graded according to the Early Treatment of Diabetic Retinopathy Severity score, and retinal venous and arterial diameters were measured.
Mean estimated glomerular filtration rate (eGFR) was 46.5 ± 15.4 mL/min/1.73 m(2), mean serum phosphate was 3.7 ± 0.6 mg/dl and median plasma C-terminal FGF23 was 133 RU/mL (interquartile range 87.2, 217.8 RU/mL). In multivariable ordinal logistic regression models, higher serum phosphate was associated with greater retinopathy severity independent of hypertension, diabetes, CKD severity and FGF23 [adjusted odds ratio of being in one higher category of retinopathy severity: 1.19 per 1 standard deviation increase; 95% confidence interval (CI) 1.05, 1.36; P = 0.007]. Presence of diabetes or hypertension did not modify the results. Higher serum phosphate was also independently associated with greater retinal venous diameter (multivariable-adjusted 1.70 µm increase per 1 standard deviation increase in phosphate; 95% CI 0.46, 2.93; P = 0.007). FGF23 levels were not independently associated with retinopathy severity or retinal venous diameter, and neither FGF23 nor phosphate was associated with retinal arterial diameter.
Among individuals with moderate-to-severe CKD, higher serum phosphate but not FGF23 was independently associated with more severe retinopathy and microvascular retinal venous dilatation.
慢性肾脏病(CKD)患者循环血中磷酸盐和成纤维细胞生长因子23(FGF23)浓度升高与心血管疾病的发病机制有关。视网膜病变是CKD微血管疾病的常见表现,但尚未对其与磷酸盐和FGF23的关系进行研究。我们检验了这样一个假设:在CKD患者中,较高的血清磷酸盐水平与更严重的视网膜病变相关,且独立于FGF23和已知的视网膜病变危险因素。
在一项对1800名接受眼底摄影的慢性肾功能不全队列研究参与者的横断面分析中,我们检验了血清磷酸盐和血浆FGF23与视网膜病变的关系。根据糖尿病视网膜病变早期治疗严重程度评分对视网膜病变严重程度进行分级,并测量视网膜静脉和动脉直径。
平均估计肾小球滤过率(eGFR)为46.5±15.4 mL/min/1.73 m²,平均血清磷酸盐为3.7±0.6 mg/dl,血浆C末端FGF23中位数为133 RU/mL(四分位间距87.2,217.8 RU/mL)。在多变量有序逻辑回归模型中,较高的血清磷酸盐水平与更严重的视网膜病变相关,且独立于高血压、糖尿病、CKD严重程度和FGF23[视网膜病变严重程度每升高一个等级的校正比值比:每增加1个标准差为1.19;95%置信区间(CI)1.05,1.36;P = 0.007]。糖尿病或高血压的存在并未改变结果。较高的血清磷酸盐水平还与更大的视网膜静脉直径独立相关(磷酸盐每增加1个标准差,多变量校正后视网膜静脉直径增加1.70 µm;95% CI 0.46,2.93;P = 0.007)。FGF23水平与视网膜病变严重程度或视网膜静脉直径无独立相关性,FGF23和磷酸盐均与视网膜动脉直径无关。
在中重度CKD患者中,较高的血清磷酸盐水平而非FGF23与更严重的视网膜病变和视网膜微血管静脉扩张独立相关。